STAAR Surgical (NASDAQ: STAA) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.
Earnings & Valuation
This table compares STAAR Surgical and The Cooper Companies’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|STAAR Surgical||$90.61 million||6.45||-$2.13 million||$0.01||1,410.00|
|The Cooper Companies||$2.14 billion||5.00||$372.90 million||$9.70||22.47|
This is a breakdown of current ratings and recommmendations for STAAR Surgical and The Cooper Companies, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|The Cooper Companies||0||7||6||0||2.46|
STAAR Surgical presently has a consensus target price of $20.50, suggesting a potential upside of 45.39%. The Cooper Companies has a consensus target price of $264.90, suggesting a potential upside of 21.52%. Given STAAR Surgical’s stronger consensus rating and higher probable upside, research analysts plainly believe STAAR Surgical is more favorable than The Cooper Companies.
This table compares STAAR Surgical and The Cooper Companies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|The Cooper Companies||7.83%||16.90%||10.11%|
Institutional & Insider Ownership
79.0% of STAAR Surgical shares are held by institutional investors. Comparatively, 98.5% of The Cooper Companies shares are held by institutional investors. 5.6% of STAAR Surgical shares are held by insiders. Comparatively, 1.6% of The Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
STAAR Surgical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
The Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. STAAR Surgical does not pay a dividend. The Cooper Companies pays out 0.6% of its earnings in the form of a dividend.
The Cooper Companies beats STAAR Surgical on 9 of the 16 factors compared between the two stocks.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.
About The Cooper Companies
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services focusing on women's health, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (ob/gyns) medical offices, and fertility clinics. In addition, the company offers carrier screening, preimplantation genetic screening, and preimplantation genetic diagnosis used in IVF process; IVF medical devices, systems, and equipment; and PARAGARD, a non-hormonal, copper intrauterine device for birth control. Further, The Cooper Companies, Inc. offers its products under Biofinity, clarity 1day, MyDay, and Proclear 1 Day brand name. The company markets its products through a network of field sales representatives, independent agents, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in Pleasanton, California.
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.